American Journal of Clinical Dermatology

, Volume 6, Issue 3, pp 151–164 | Cite as

Lentigo Maligna

Prognosis and Treatment Options
  • Olivia Stevenson
  • Imtiaz Ahmed
Therapy in Practice


Lentigo maligna is a premalignant melanocytic neoplasm occurring on the sun-exposed skin of the middle-aged and elderly. It is believed to represent the in situ phase of lentigo maligna melanoma and, as such, cure is usually the aim of treatment. However, factors such as site and size of lesion and patient co-morbidities may influence the treatment modality undertaken. Surgical excision is the treatment of choice to obtain clinical and histologic clearance, but many other modalities have been used with variable success. Mohs micrographic surgery is associated with the lowest recurrence rate at 4–5%, but conventional surgery, cryotherapy and radiotherapy also yield good results, with recurrence rates in the order of 7–10%. Other treatments have been tried but currently there are not enough data to support their routine use. In order to make the best decision regarding appropriate management of lentigo maligna, the dermatologist or surgeon must be aware of all the options available and the evidence supporting their use.


Melanoma Tretinoin Imiquimod Azelaic Acid Tazarotene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.


  1. 1.
    Farshad A, Burg G, Panizzon R, et al. A retrospective study of 150 patients with lentigo maligna and lentigo mal igna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatology. 2002; 146: 1042–6CrossRefGoogle Scholar
  2. 2.
    Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1995 Dec; 33 (6): 923–36PubMedCrossRefGoogle Scholar
  3. 3.
    Durnick A, Stolz W, Landthaler M, et al. Lentigo maligna and lentigo maligna melanoma in young adults. Dermatol Surg. 2004; 30 (5): 813–6PubMedCrossRefGoogle Scholar
  4. 4.
    Kuffk EG, Gage AA. Cryosurgery for lentigo maligna. J Am Acad Dermatol. 1994 Jul; 31 (1): 75–8CrossRefGoogle Scholar
  5. 5.
    Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer. 1968 May; 21: 893–901PubMedCrossRefGoogle Scholar
  6. 6.
    Hutchinson J. Notes on the cancerous process and on new growths in general. Arch Surg (London). 1890; 2: 83–6Google Scholar
  7. 7.
    Hutchinson J. On tissue dotage. Arch Surg (London). 1892; 3: 315–22Google Scholar
  8. 8.
    Hutchinson J. On cancer. Arch Surg (London). 1893; 4: 61–3Google Scholar
  9. 9.
    Hutchinson J. Lentigo melanosis: a further report. Arch Surg (London). 1894; 5: 53–6Google Scholar
  10. 10.
    Hutchinson J. President’s address at the Third International Congress of Dermatology. Arch Surg (London). 1896; 7: 297–317Google Scholar
  11. 11.
    Dubreuilh MW. Lentigo malin des vieillards. Ann Dermatol Syphiligr (Paris). 1894 Aug; 5: 1092–9Google Scholar
  12. 12.
    Dubreuilh MW. De la mélanose circonscrite précancéreuse. Ann Dermatol Syphiligr (Paris). 1912; 3: 129–51, 205–30Google Scholar
  13. 13.
    The British Association of Dermatologists and the Melanoma Study Group. UK guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002; 146: 7–17Google Scholar
  14. 14.
    Jackson R, Williamson GS, Beattie WG. Lentigo maligna and lentigo maligna melanoma. CMAJ. 1966; 95: 846–51Google Scholar
  15. 15.
    Davis J, Pack GT, Higgins GK. Melanotic freckle of Hutchinson. Am J Surg. 1967; 113: 457–63PubMedCrossRefGoogle Scholar
  16. 16.
    Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987; 116: 303–10PubMedCrossRefGoogle Scholar
  17. 17.
    Mishima Y. Melanocytic and nevocytic malignant melanomas: cellular and subcellular differentiation. Cancer. 1967; 20: 632–49PubMedCrossRefGoogle Scholar
  18. 18.
    Grionspan D, Paz A, Abulafia J, et al. Melanoma (léntigo maligna de Hutchinson) de regression espontanea: caso de interés inmunólogico. Med Cután Ibero Lat Am. 1980; 8: 33–45Google Scholar
  19. 19.
    Coleman WP, Davis RS, Reed RJ, et al. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol. 1980 Jun; 6: 476–9PubMedGoogle Scholar
  20. 20.
    Bartoli C, Bono A, Clemente C, et al. Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer. 1996; 77: 888–92PubMedCrossRefGoogle Scholar
  21. 21.
    Clark Jr WH, Mihm Jr MC. Lentigo maligna and lentigo maligna melanoma. Am J Pathol. 1969; 55: 39–54PubMedGoogle Scholar
  22. 22.
    Clark Jr WH, Ainsworth AM, Bernardino EA, et al. The developmental biology of primary human malignant melanomas. Semin Oncol. 1975; 2: 83–103PubMedGoogle Scholar
  23. 23.
    Knudsen EA, Thomsen HK. Lentigo malignant melanoma. Ugeskr Laeger. 1994; 156: 4251–2PubMedGoogle Scholar
  24. 24.
    Austin WE. Melanotic freckle as a precursor of malignant melanoma: report of a case. Can J Surg. 1963; 6: 363–6PubMedGoogle Scholar
  25. 25.
    Costello MJ, Fisher SB, DeFeo CP. Melanotic freckle. Arch Dermatol. 1959; 80: 753–71PubMedCrossRefGoogle Scholar
  26. 26.
    Koh HK, Michalik EE, Sober AJ, et al. Lentigo maligna has no better prognosis than other types of melanoma. J Clin Oncol. 1984 Sep; 2 (9): 994–1001PubMedGoogle Scholar
  27. 27.
    Kelly JW. Following lentigo maligna may not prevent the development of lifethreatening melanoma. Arch Dermatol. 1992 Jan; 128 (5): 657–60PubMedCrossRefGoogle Scholar
  28. 28.
    Albert LS, Fewkes J, Sober AJ. Metastatic lentigo maligna melanoma. J Dermatol Surg Oncol. 1990; 16: 56–8PubMedGoogle Scholar
  29. 29.
    Michalik EE, Fitzpatrick TB, Sober AJ. Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma: report of two cases. Arch Dermatol. 1983; 119: 831–5PubMedCrossRefGoogle Scholar
  30. 30.
    Penneys NS. Microinvasive lentigo maligna melanoma. J Am Acad Dermatol. 1987 Oct; 17 (4): 675–80PubMedCrossRefGoogle Scholar
  31. 31.
    Somach SC, Taira JW, Pitha JV, et al. Pigmented lesions in actinically damaged skin. Arch Dermatol. 1996; 132: 1297–302PubMedCrossRefGoogle Scholar
  32. 32.
    Cohen LM, McCall MW, Zax RH. Mobs micrographic surgery for lentigo maligna melanoma: a follow up study. Dermatol Surg. 1998; 24 (6): 673–7PubMedCrossRefGoogle Scholar
  33. 33.
    Carucci JA. Treatment of lentigo maligna. Cutis. 2001; 67: 389–92PubMedGoogle Scholar
  34. 34.
    Agarwal-Antal N, Bowen BG, Gerwels JW. Histologic evaluation of lentigo maligna with permanent section: implications regarding current guidelines. J Am Acad Dermatol. 2002 Nov; 47 (5): 743–8PubMedCrossRefGoogle Scholar
  35. 35.
    Grande DJ, Koranda FC, Whittaker DC. Surgery of extensive, sub-clinical lentigo maligna melanoma. J Dermatol Surg Oncol. 1982; 8: 493–6PubMedGoogle Scholar
  36. 36.
    Johnson TM, Smith JW, Nelson BR, et al. Current therapy for cutaneous melanoma. J Am Acad Dermatol. 1995; 32: 689–707PubMedCrossRefGoogle Scholar
  37. 37.
    McEwan LE, Buchanan MRC. Invasive melanoma in the donor and recipient sites of a Hutchinson’s freckle transplanted in a split skin graft. Aust N Z J Surg. 1986; 56: 81–4PubMedCrossRefGoogle Scholar
  38. 38.
    Kelly RI, Cook MG, Mortimer PS. Aggressive amelanotic lentigo maligna. Br J Dermatol. 1994; 131: 562–5PubMedCrossRefGoogle Scholar
  39. 39.
    Litwan MS, Kremetz ET, Mansell PW, et al. Topical chemotherapy of lentigo maligna with 5-fluorouracil. Cancer. 1975; 3: 721–33CrossRefGoogle Scholar
  40. 40.
    Kroumpouzos G, Frank EW, Albertini JG, et al. Lentigo maligna with spread onto oral mucosa. Arch Dermatol. 2002; 138 (9): 1216–20PubMedCrossRefGoogle Scholar
  41. 41.
    Mahendran R, Newton-Bishop JA. Survey of UK current practice in the treatment of lentigo maligna. Br J Dermatol. 2001; 144: 71–6PubMedCrossRefGoogle Scholar
  42. 42.
    Gasper ZS, Dawber RPR. Treatment of lentigo maligna. Australas J Dermatol. 1997; 38: 1–8CrossRefGoogle Scholar
  43. 43.
    Davalbhakta A, Hamilton S, Grant JW, et al. Spread of a recurrent lentigo maligna into a graft: a case for conservative treatment. Br J Plast Surg. 2001; 54 (3): 253–6PubMedCrossRefGoogle Scholar
  44. 44.
    Pitman GH, Kopf AW, Bart RS, et al. Treatment of lentigo maligna melanoma. J Dermatol Surg Oncol. 1979 Sep; 5: 727–37PubMedGoogle Scholar
  45. 45.
    Tsang RW, Liu F-F, Wells W, et al. Lentigo maligna of the head and neck. Arch Dermatol. 1994; 130: 1008–12PubMedCrossRefGoogle Scholar
  46. 46.
    Marsden JR, Sanders DSA. Lentigo maligna: surgical treatment. J Fur Acad Dermatol Venereol. 1995; 5 (1001): 100–2Google Scholar
  47. 47.
    Bub JL, Berg D, Slee A, et al. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004; 140 (5): 552–8PubMedCrossRefGoogle Scholar
  48. 48.
    Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol. 1999; 40 (1): 25–30PubMedCrossRefGoogle Scholar
  49. 49.
    Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol. 1994; 31: 79–85PubMedCrossRefGoogle Scholar
  50. 50.
    Montagna W, Kirchner S, Carlisle K. Histology of sun damaged skin. J Am Acad Dermatol. 1989; 21: 907–18PubMedCrossRefGoogle Scholar
  51. 51.
    National Institutes of Health Consensus Conference. Diagnosis and treatment of early melanoma. JAMA. 1992; 268: 1314–9CrossRefGoogle Scholar
  52. 52.
    Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2001; 140 (9): 1087–92CrossRefGoogle Scholar
  53. 53.
    Preston PW, Matey P, Sanders DSA, et al. Surgical treatment of lentigo maligna using 2-mm excision margins [abstract]. Br J Dermatol; 2003; 149 (64): 109–10Google Scholar
  54. 54.
    Dhawan SS, Wolf DJ, Rabinovitz HS, et al. Lentigo maligna: the use of rush permanent sections in therapy. Arch Dermatol. 1990; 126: 928–30PubMedCrossRefGoogle Scholar
  55. 55.
    Malhotra R, Chan C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology. 2003; 110 (10): 2011–8PubMedCrossRefGoogle Scholar
  56. 56.
    Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg. 1984; 73: 492–6PubMedCrossRefGoogle Scholar
  57. 57.
    Cohen LM, McCall MW, Hodge SJ, et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mobs’ micrographic surgery aided by rush permanent sections. Cancer. 1994 Jun; 73: 2964–70PubMedCrossRefGoogle Scholar
  58. 58.
    Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins or melanoma. J Am Acad Dermatol. 1991; 24: 403–7CrossRefGoogle Scholar
  59. 59.
    Nield DV, Saad MN, Khoo CT, et al. Tumour thickness in malignant melanoma: the limitations of frozen section. Br J Plast Surg. 1988; 41: 403–7PubMedCrossRefGoogle Scholar
  60. 60.
    Gross EA, Anderson WK, Rogers GS. Mobs Micrographic Excision of Lentigo Maligna Using Mel-5 for margin control. Arch Dermatol. 1999; 135: 15–7PubMedCrossRefGoogle Scholar
  61. 61.
    Stonecipher MR, Leshin B, Patrick J. Management of lentigo maligna and lentigo maligna melanoma with paraffin-embedded tangential sections: utility of immunoperoxidase staining and supplemental vertical sections. J Am Acad Dermatol Oct. 1993; 29 (4): 589–94CrossRefGoogle Scholar
  62. 62.
    Johnson TM, Headington JT, Baker SR, et al. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: The “Square” procedure. J Am Acad Dermatol. 1997 Nov; 37 (5): 758–64PubMedCrossRefGoogle Scholar
  63. 63.
    Collins P, Rogers S, Goggin M, et al. Cryotherapy of lentigo maligna. Clin Exp Dermatol. 1991; 16: 433–5PubMedCrossRefGoogle Scholar
  64. 64.
    Lorenz E. Cryosurgery for lentigo maligna [short communication]. Dermatol Times. 1983; 4: 29Google Scholar
  65. 65.
    Zacarian SA. Cryosurgery for skin cancer and cutaneous disorders. St Louis (MO): Mosby, 1985: 199–214Google Scholar
  66. 66.
    Bohler-Sommeregger K, Schuller-Petrovic S, Neumann R, et al. Cryosurgery for lentigo maligna. Plast Reconstr Surg. 1992; 90: 436–40PubMedCrossRefGoogle Scholar
  67. 67.
    Dawber RPR, Wilkinson JD. Melanotic freckle of Hutchinson: treatment of macular and nodular phases with cryotherapy. Br J Dermatol. 1979; 101: 47–9PubMedCrossRefGoogle Scholar
  68. 68.
    Gage AA, Meenaghan MA, Natiella JR, et al. Sensitivity of pigmented mucosa and skin to freezing injury. Cryobiology. 1979; 16: 348–61PubMedCrossRefGoogle Scholar
  69. 69.
    Zacarian SA. Cryosurgical treatment of lentigo maligna. Arch Dermatol. 1982; 118 (2): 89–92PubMedCrossRefGoogle Scholar
  70. 70.
    Kuflik EG. Cryosurgery for lentigo maligna: a report of 4 cases. J Dermatol Surg Oncol. 1980; 6 (6): 432–5PubMedGoogle Scholar
  71. 71.
    Burge SM, Dawber RP. Cryotherapy for lentigo maligna [letter]. J Dermatol Surg Oncol. 1984; 10 (11): 910PubMedGoogle Scholar
  72. 72.
    Bohler-Sommeregger K, Schuller-Petrovic S, Knobler R, et al. Reactive lentiginous hyperpigmentation after cryosurgery for lentigo maligna. J Am Acad Dermatol. 1992; 27: 523–6PubMedCrossRefGoogle Scholar
  73. 73.
    Miescher G. Ober melanotische Prdeancerosen. Oncologia. 1954; 7: 92–4PubMedCrossRefGoogle Scholar
  74. 74.
    de Groot WP. Provisional results of treatment of the mélanose précancéreuse circonscrite Dubreuilh by bucky rays. Dermatologica. 1968; 136: 429–31PubMedCrossRefGoogle Scholar
  75. 75.
    Kopf AW, Bart RS, Gladstein AH. Treatment of melanotic freckle with x-rays. Arch Dermatol. 1976; 112: 801–7PubMedCrossRefGoogle Scholar
  76. 76.
    Richter VG, Kleine-Natrop HE. Die Behandlung der melanosis circumscripta praecancerosa mit besonderer berücksichtigung der dermatologischen grenzstrahltherapie. Dermatol Monatsschr. 1977; 163: 195–202PubMedGoogle Scholar
  77. 77.
    Petratos MA, Kopf AW, Bart RS, et al. Treatment of melanotic freckle with x rays. Arch Dermatol. 1972; 106: 189–94PubMedCrossRefGoogle Scholar
  78. 78.
    Storck H. Treatment of melanotic freckles by radiotherapy. J Dermatol Surg Oncol. 1977; 3: 293–4PubMedGoogle Scholar
  79. 79.
    Arma-Szlachcic M, Ott F, Storck H. Zur Strahlentherapie melanotischen Prdcancerosen. Hautartzt. 1970; 21: 505–8Google Scholar
  80. 80.
    Duncuart F, Harwood AR, Fitzpatrick PJ. The radiotherapy of lentigo maligna and lentigo maligna melanoma of the head and neck. Cancer. 1980; 45 (9): 2279–83CrossRefGoogle Scholar
  81. 81.
    Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radial Oncol Biol Phys. 1983; 9: 1019–21CrossRefGoogle Scholar
  82. 82.
    Panizzon RG. Radiotherapy of benign and premalignant skin diseases [abstract]. J Fur Acad Dermatol Venereol. 1997; 9 Suppl. 1: S62CrossRefGoogle Scholar
  83. 83.
    Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000; 43 (3): 477–82PubMedCrossRefGoogle Scholar
  84. 84.
    Harwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1982; 6: 310–6PubMedCrossRefGoogle Scholar
  85. 85.
    Shaw HC. Lentigo maligna: report of one case treated with radium. Am J Cancer. 1931; 15: 1557–69Google Scholar
  86. 86.
    Corsi H. Three cases of mélanose circonscrite précancéreuse. Proc R Soc Med. 1938; 32: 261–3Google Scholar
  87. 87.
    Berridge JK, Morgan DA. A comparison of late cosmetic results following two different radiotherapy techniques for treating basal cell carcinoma. Clin Oncol (R Coll Radiol). 1997; 9 (6): 400–2CrossRefGoogle Scholar
  88. 88.
    Nazzaro-Porro M, Passi S, Balul L, et al. Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol. 1979; 72: 296–305PubMedCrossRefGoogle Scholar
  89. 89.
    Breathnach AS, Martin B, Nazzaro-Porro M, et al. Effect of dicarboxylic acids on normal human melanocytes in dispersed tissue culture. Br J Dermatol. 1993; 32: 363–4Google Scholar
  90. 90.
    Nazzaro-Porro M. The use of azelaic acid in hyperpigmentation. Rev Contemp Pharmacother. 1993; 4: 415–23Google Scholar
  91. 91.
    Liebl H, Stingl G, Pehamberger H, et al. Inhibition of DNA synthesis of melanoma cells by azelaic acid. J Invest Dermatoll. 1984; 85: 417–22CrossRefGoogle Scholar
  92. 92.
    Nazzaro-Porro M, Passi S, Zina G, et al. 10 years experience treating lentigo maligna with topical azelaic acid. Acta Derm Venereol Suppl (Storch). 1989; 143: 49–57Google Scholar
  93. 93.
    Nazzaro-Porro M, Passi S, Zinna G, et al. Effect of azelaic acid on human malignant melanoma. Lancet. 1980; I: 1109–11CrossRefGoogle Scholar
  94. 94.
    Breathnach AS, Nazzaro-Porro M, Passi S. Azelaic acid. Br J Dermatol. 1984; 111: 115–20PubMedCrossRefGoogle Scholar
  95. 95.
    Prieto MAR, Lopez PM, Gonzalez IR, et al. Treatment of Lentigo Maligna with azelaic acid. Int J Dermatol. 1993; 32 (5): 363–4CrossRefGoogle Scholar
  96. 96.
    Doherty VR. Azelaic acid in lentigo maligna [letter]. Br J Dermatol. 1987; 116: 606CrossRefGoogle Scholar
  97. 97.
    Ertle T, Wiskermann A, Janner M. Local treatment of lentigo maligna with azelaic acid. Arch Dermatol Res. 1981; 271: 197–203CrossRefGoogle Scholar
  98. 98.
    McClean DI, Peter KK. Apparent progression of lentigo maligna to invasive melanoma during treatment with topical azelaic acid. Br J Dermatol. 1986; 114: 685–9CrossRefGoogle Scholar
  99. 99.
    Arndt KA. Argon laser treatment of lentigo maligna. J Am Acad Dermatol. 1984; 10: 953–7PubMedCrossRefGoogle Scholar
  100. 100.
    Arndt KA. New pigmented macule appearing 4 years after argon laser treatment of lentigo maligna [letter]. J Am Acad Dermatol. 1986; 14: 1092PubMedCrossRefGoogle Scholar
  101. 101.
    Kopera D. Treatment of Lentigo maligna with the carbon dioxide laser. Arch Dermatol. 1995; 131: 735–6PubMedCrossRefGoogle Scholar
  102. 102.
    Thissen M, Westerhof W. Lentigo maligna treated with ruby laser[letter]. Acta Derm Venersol. 1997; 77: 163Google Scholar
  103. 103.
    Orten SS, Waner M, Dinehart SM, et al. Q switched neodymium: yttriumaluminium-garnet laser treatment of lentigo maligna. Otolaryngol Head Neck Surg. 1999 Mar; 120 (3): 296–302PubMedCrossRefGoogle Scholar
  104. 104.
    Iyer S, Goldman M. Treatment of lentigo maligna with combination laser therapy: recurrence at 8 months after initial resolution. J Cosmet Laser Ther. 2003; 5 (1): 49–52Google Scholar
  105. 105.
    Dorr RT. Interferon-alpha in malignant and viral diseases: a review. Drugs. 1993; 45: 177–211PubMedCrossRefGoogle Scholar
  106. 106.
    Punt CJ. The use of interferon-alpha in the treatment of cutaneous melanoma: a review. Melanoma Res. 1998; 8: 95–104PubMedCrossRefGoogle Scholar
  107. 107.
    von Wussow P, Block B, Hartmann F, et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer. 1988; 61: 1071–4CrossRefGoogle Scholar
  108. 108.
    Comejo P, Vanaclocha F, Polimon I, et al. Intralesional interferon treatment of lentigo maligna. Arch Dermatol. 2000; 136: 428–30CrossRefGoogle Scholar
  109. 109.
    Chanco Turner ML, Moshell AN, Corbet DW, et al. Clearing of melanoma in situ with intralesional interferon alpha in a patient with xeroderma pigmentosum. Arch Dermatol. 1994; 130: 1491–4CrossRefGoogle Scholar
  110. 110.
    Carucci JA. Intralesional interferon alpha for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. Arch Dermatol. 2000; 136: 1415–6PubMedCrossRefGoogle Scholar
  111. 111.
    Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998; 110: 734–9PubMedCrossRefGoogle Scholar
  112. 112.
    Michalopoulos P, Yawalkar N, Bronnimann M, et al. Characterisation of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004; 151 (4): 903–6PubMedCrossRefGoogle Scholar
  113. 113.
    Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000; 143: 843–5PubMedCrossRefGoogle Scholar
  114. 114.
    Ormond P, Blasdale C, Leonard N, et al. Treatment of lentigo maligna with imiquimod [abstract]. Br J Dermatol. 2002; 147 Suppl. 62: 57Google Scholar
  115. 115.
    Powell AM, Russell-Jones R. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol. 2004; 50 (5): 792–6PubMedCrossRefGoogle Scholar
  116. 116.
    Chapman MS. Histological resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003; 139: 943–4PubMedCrossRefGoogle Scholar
  117. 117.
    Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol. 2003; 139: 944–5PubMedCrossRefGoogle Scholar
  118. 118.
    Fisher GH, Lang PG. Treatment of melanoma in situ on sun damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003; 139: 943–4CrossRefGoogle Scholar
  119. 119.
    Kamin A, Eigentler TK, Radny P, et al. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol. 2005; 52 (2 Suppl. 1): 51–2PubMedCrossRefGoogle Scholar
  120. 120.
    Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg. 2004; 30 (12 Pt 2): 1543–5PubMedCrossRefGoogle Scholar
  121. 121.
    Kupfer-Bessaguet I, Guillet G, Misery L, et al. Topical imiquimod treatment of lentigo maligna: clinical and histological evaluation. J Am Acad Dermatol. 2004; 51 (4): 635–9PubMedCrossRefGoogle Scholar
  122. 122.
    Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003; 149 Suppl. 66: 66–70PubMedCrossRefGoogle Scholar
  123. 123.
    Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004; 29 (1): 15–21PubMedCrossRefGoogle Scholar
  124. 124.
    Fleming CJ, Bryden AM, Evans A, et al. A pilot study of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004; 151 (2): 485–8PubMedCrossRefGoogle Scholar
  125. 125.
    Ryan RF, Krementz ET, Litwin MS. A role for topical 5-fluorouracil therapy in melanoma. J Surg Oncol. 1988; 33: 250–6CrossRefGoogle Scholar
  126. 126.
    Santos GW. Immunosuppressive drugs. Fed Proc. 1967; 26: 907–13PubMedGoogle Scholar
  127. 127.
    Nio Y, Imai S, Shiraishi T, et al. Lymphocytes anticancer chemosensitivity testing in vitro: an approach to predict immunosuppressive effect of anticancer agents. Clin Lab Immunol. 1989; 29 (3): 141–5Google Scholar
  128. 128.
    Meyskens Jr FL. Modulation of abnormal growth by retinoids: a clinical perspective of the biological phenomena. Life Sci. 1981; 28: 2323–7PubMedCrossRefGoogle Scholar
  129. 129.
    Rivers JK, McCarthy WH. No effect of topical tretinoin on lentigo maligna [letter]. Arch Dermatol. 1991; 127: 129PubMedCrossRefGoogle Scholar
  130. 130.
    Chimenti S, Carrozzo AM, Citarella L, et al. Treatment of lentigo maligna with tazarotene 0.1% gel. J Am Acad Dermatol. 2004; 50 (1): 101–3PubMedCrossRefGoogle Scholar
  131. 131.
    Ries LA, Hankey BF, Miller BA, et al. Cancer statistics review 1973–88. NIH Publication #91-2789. Washington (DC): National Cancer Institute, US Government Printing Office, 1991Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of DermatologyWalsgrave HospitalCoventryUK

Personalised recommendations